A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm

作者：Casolari D A; Nguyen T; Butcher C M; Iarossi D G; Hahn C N; Bray S C; Neufing P; Parker W T; Feng J; Maung K Z Y; Wee A; Vidovic L; Kok C H; Bardy P G; Branford S; Lewis I D; Lane S W; Scott H S; Ross D M; D'Andrea R J^*

来源：Scientific Reports, 2017, 7(1): 2467.

DOI：10.1038/s41598-017-02655-7

We describe a novel ERBB1/EGFR somatic mutation (p.C329R; c.985T > C) identified in a patient with JAK2(V617F) Polycythaemia Vera (PV). This substitution affects a conserved cysteine residue in EGFR domain 2 and leads to the formation of a ligand-independent covalent receptor dimer, associated with increased transforming potential. Aberrant signalling from the EGFR(C329R) receptor is cell type-dependent and in the TF1.8 erythroid cell line expression of this mutant suppresses EPO-induced differentiation. Clonal analysis shows that the dominant JAK2(V617F)-positive clone in this PV patient harbors EGFR(C329R), thus this mutation may contribute to clonal expansion. Somatic mutations affecting other ERBB and related receptor tyrosine kinases are observed in myeloproliferative neoplasms (MPN), and we show elevated EGFR levels in MPN samples, consistent with previous reports. Thus activation of this group of receptors, via multiple mechanisms, may contribute to clonal growth and survival of the JAK2(V617F) disease clone in MPN.

• 出版日期2017-5-26
• 单位河北医科大学